ZielBio

ZielBio is an early-stage biotechnology company that identifies novel high value disease targets and develops therapeutic interventions to improve patient outcomes. Its proprietary drug discovery platform Zielfind™ combines the power of functional, high throughput screening with large content data analytics to identify high value targets. ZielBio has a promising pipeline of therapies and targets, including lead compound ZB131, a proprietary monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind™. ZielBio closed a Series A financing round in September, 2019.